

Leukemia & Lymphoma >

Volume 56, 2015 - [Issue 4](#)

251 | 3 | 0  
Views | CrossRef citations to date | Altmetric

Original Article: Clinical

# Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

Eric Jacobsen , Olga Pozdnyakova, Robert Redd, David C. Fisher, David M. Dorfman, Paola Dal Cin, ... [show all](#)

Pages 993-998 | Received 03 Jun 2014, Accepted 30 Jun 2014, Accepted author version posted online: 11 Jul 2014, Published online: 20 Aug 2014

 Cite this article  <https://doi.org/10.3109/10428194.2014.941835>



Sample our  
Medicine, Dentistry, Nursing  
& Allied Health Journals  
>> [Sign in here](#) to start your access  
to the latest two volumes for 14 days

-  Full Article  Figures & data  References  Supplemental  Citations  Metrics
-  Reprints & Permissions [Read this article](#) [Share](#)

## Abstract

Platelet derived growth factor- $\alpha$  (PDGFR- $\alpha$ ) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR- $\alpha$  expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR- $\alpha$  fusion and/or PDGFR- $\alpha$  amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis

of PDGFR- $\alpha$  by immunohistochemistry and three of these patients' tumors expressed PDGFR- $\alpha$ . Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR- $\alpha$  expression was not required for study entry.

Keywords::

Lymphoma   imatinib   PDGFR- $\alpha$

Potential conflict of interest:

[Disclosure](#) forms provided by the authors are available with the full text of this article at [www.informahealthcare.com/lal](http://www.informahealthcare.com/lal).

Related research 

People also read

Recommended articles

Cited by  
3

## Information for

[Authors](#)

[R&D professionals](#)

[Editors](#)

[Librarians](#)

[Societies](#)

## Opportunities

[Reprints and e-prints](#)

[Advertising solutions](#)

[Accelerated publication](#)

[Corporate access solutions](#)

## Open access

[Overview](#)

[Open journals](#)

[Open Select](#)

[Dove Medical Press](#)

[F1000Research](#)

## Help and information

[Help and contact](#)

[Newsroom](#)

[All journals](#)

[Books](#)

## Keep up to date

Register to receive personalised research and resources by email



Sign me up



Copyright © 2026 Informa UK Limited [Privacy policy](#)

[Cookies](#) [Terms & conditions](#) [Accessibility](#)

Registered in England & Wales No. 01072954  
5 Howick Place | London | SW1P 1WG



**Taylor & Francis**  
by informa